Cytomegalovirus-targeted immunotherapy and glioblastoma: Hype or hope?

Sherise D. Ferguson*, Visish M. Srinivasan, Michael GZ Ghali, Amy B. Heimberger

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Malignant gliomas, including glioblastoma (GBM), are the most common primary brain tumors. Despite extensive research only modest gains have been made in long-term survival. Standard of care involves maximizing safe surgical resection followed by concurrent chemoradiation with temozolomide. Immunotherapy for GBM is an area of intense research in recent years. New immunotherapies, although promising, have not been integrated into standard practice. Human cytomegalovirus (HCMV) is a DNA virus of the family Herpesviridae. Human seroprevalence is approximately 80%, and in most cases, is associated with asymptomatic infection. HCMV may be an important agent in the initiation, promotion and/or progression of tumorigenesis. Regardless of a possible etiologic role in GBM, interest has centered on exploiting this association for development of immunomodulatory therapies.

Original languageEnglish (US)
Pages (from-to)413-423
Number of pages11
Issue number4
StatePublished - Apr 2016
Externally publishedYes


  • adoptive transfer therapy
  • cytomegalovirus (CMV)
  • dendritic cell
  • glioblastoma
  • glioma
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Cytomegalovirus-targeted immunotherapy and glioblastoma: Hype or hope?'. Together they form a unique fingerprint.

Cite this